California Public Employees Retirement System Reduces Position in Boston Scientific Corporation $BSX

California Public Employees Retirement System decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 24.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,261,265 shares of the medical equipment provider’s stock after selling 750,748 shares during the period. California Public Employees Retirement System’s holdings in Boston Scientific were worth $141,894,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Boston Scientific by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares in the last quarter. State Street Corp lifted its position in shares of Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after buying an additional 920,495 shares in the last quarter. Capital World Investors grew its stake in shares of Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after acquiring an additional 502,627 shares during the period. Norges Bank bought a new position in shares of Boston Scientific during the 4th quarter valued at approximately $2,199,395,000. Finally, Morgan Stanley increased its holdings in Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after acquiring an additional 2,246,308 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on BSX. Needham & Company LLC decreased their target price on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Royal Bank Of Canada reduced their price objective on shares of Boston Scientific from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Leerink Partners decreased their price objective on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research report on Thursday, May 28th. Robert W. Baird set a $70.00 target price on shares of Boston Scientific in a report on Thursday, May 28th. Finally, Evercore set a $65.00 price target on Boston Scientific in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $79.84.

Insider Buying and Selling at Boston Scientific

In other news, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 9,800 shares of company stock worth $554,012. Insiders own 0.34% of the company’s stock.

Boston Scientific Trading Down 1.5%

Shares of BSX opened at $43.95 on Friday. The firm has a market cap of $65.33 billion, a P/E ratio of 18.39, a price-to-earnings-growth ratio of 0.84 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company has a 50 day simple moving average of $48.18 and a two-hundred day simple moving average of $65.87.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the previous year, the firm earned $0.75 earnings per share. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts expect that Boston Scientific Corporation will post 3.35 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.